Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy reduced the risk of disease progression or death versus cabazitaxel (Jevtana) in men with previously treated metastatic ...

Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (177 Lu). We performed a systematic review and meta-analysis to ...

An investigational radioligand therapy targeting prostate-specific membrane antigen (PSMA) delayed disease progression and improved survival for patients with metastatic castration-resistant prostate ...

At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG's radiopharmaceutical lutetium-177-PSMA-617 ...

In men with newly diagnosed metastatic hormone-sensitive prostate cancer, adding lutetium-177 PSMA-617 (177 Lu-PSMA-617) to standard hormone therapy led to a statistically significant improvement in ...

Lutetium-177-PSMA-617 (177Lu-PSMA-617), a type of targeted radiation therapy, is effective for men with advanced prostate cancer, even if they were previously treated with another radiation therapy ...

Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a good ...

Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer.

Treatment with 177 lutetium-PSMA-617 (177 Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223 radium (223 Ra), ...

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer ...